Current Status and Future Perspective of Stenting for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis

• Published in: BioMed research international Vol. 2017; no. 2017; pp. 1 - 11
• Main Authors: Liu, Zun-Jing, Chen, Ya-Wen, Liu, Wei, Zhu, Xian-Jin, Zhou, Zhenhua, Li, Zhonghao, Chen, Zi-Yao
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; Hindawi Limited
• Subjects: Angioplasty; Animals; Arteriosclerosis; Bias; Clinical trials; Heart attacks; Hospitals; Humans; Intracranial Arteriosclerosis - pathology; Intracranial Arteriosclerosis - surgery; Meta-analysis; Patients; Quality; Review; Statistical analysis; Stents; Stroke; Studies; Veins & arteries; China
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2017/3258681

The aim of this study was to evaluate the safety and effectiveness of percutaneous transluminal angioplasty and stenting (PTAS) for intracranial atherosclerotic disease (ICAD) by conducting a meta-analysis. Two independent observers searched PubMed, EMBASE, and Cochrane Library for relevant studies up to 31 December 2016. A meta-analysis was conducted using Review Manager 5.3. Three studies involving 581 cases were included. The meta-analysis indicated that any stroke (RR = 3.13; 95% CI: 1.80–5.42), ischemic stroke (RR = 2.15; 95% CI: 1.19–3.89), and intracranial hemorrhage (RR = 14.71; 95% CI: 1.96–110.48) within 30 days in medical therapy alone were lower compared with PTAS plus medical therapy, but there were no significant differences in any stroke and ischemic stroke beyond 30 days between the two groups. There were also no significant differences in any death and myocardial infarction between the two groups. This meta-analysis demonstrated that, compared with medical therapy alone, PTAS for ICAD had a high risk of complication, but most complications in PTAS group occurred within 30 days after the operation, and beyond 30 days the PTAS was not inferior compared with medical therapy alone. Further studies are needed to reduce the periprocedural complications and reappraise the PTAS.